Publications

• Gene-corrected regulatory T cell therapy for IL2RA deficiency.Ha AS, Kalter N, Rosenberg M, Acevedo LA, Liang B, Liu W, Paruthiyil S, Sinha M, Vu A, Nguyen V, Qi Z, Krishnappa N, Shu J, Yu J, Catanzaro J, Bluestone JA, Tang Q, Urnov FD, Marson A, Hendel A, Herold KC, Shy BR, Esensten JH. Mol Ther. 2025 Dec 9; 2025 Dec 9. PMID: 41376159.
• Towards insulin independence in type 1 diabetes: Prospects for prevention and cure.Sydney GI, Perdigoto AL, Herold KC. PLoS Med. 2025 Nov; 2025 Nov 25. PMID: 41289263.
• CTLA-4 blockade shifts the B cell repertoire toward autoimmunity.Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas CR, Bouis D, Boeckers JM, Gera R, Yraita S, Clapp L, Perdigoto AL, Delmotte FR, Massad C, Bacchiocchi A, Ring AM, Kluger Y, Kluger HM, Herold KC, Meffre E. J Clin Invest. 2025 Nov 17; 2025 Sep 30. PMID: 41026527.
• Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.Savion Gaiger N, Hurwitz ME, Hafez N, Kluger HM, Herold KC, Perdigoto AL. Front Endocrinol (Lausanne). 2025; 2025 Nov 7. PMID: 41282287.
• Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab.Mathieu C, Sims EK, Chatenoud L, James EA, Atkinson MA, Herold KC. Diabetes Care. 2025 Nov 6; 2025 Nov 6. PMID: 41196630.
• The Pathogenesis of Type 1 Diabetes.Herold KC, Krischer JP. Cold Spring Harb Perspect Med. 2025 Nov 3; 2025 Nov 3. PMID: 39134388.
• Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.Sims EK, Russell WE, Cuthbertson D, Skyler JS, Jacobsen LM, Ismail HM, Redondo MJ, Nathan BM, Carr ALJ, Taylor PN, Dayan CM, Galderisi A, Herold KC, Sosenko JM. Diabetes. 2025 Nov 1. PMID: 40877213.
• The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.Chatenoud L, Herold KC, Bach JF, Bluestone JA. Cold Spring Harb Perspect Med. 2025 Oct 1; 2025 Oct 1. PMID: 39284671.
• Reversing Diabetes With Your Own Cells: Closer to the Dream.Genosar R, Coman MM, Herold KC. J Clin Endocrinol Metab. 2025 Sep 16. PMID: 39673177.
• Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.Aizenbud L, Savion Gaiger N, Perdigoto AL, Mann JE, Torres MC, Boland GM, Lawless AR, Silverman S, Schoenfeld DA, Destina JI, Hasson N, Tran T, Hurwitz M, Austin MR, Sullivan RJ, Herold KC, Kluger HM. J Immunother Cancer. 2025 Sep 10; 2025 Sep 10. PMID: 40935567.
• Replacement of Beta Cells for Type 1 Diabetes.Herold KC, Pober JS. N Engl J Med. 2025 Sep 4. PMID: 40902169.
• Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.Quandt Z, Young A, Barlow GL, Smith JA, Kusmartseva I, Dong S, Shapiro MR, Kang JH, Felton JL, Nguyen VQ, Szot G, Hassoun AA, Perdigoto AL, Herold KC, Nolan G, Bollyky PL, Brusko TM, Nakayama M, Cooper S, Anderson MS. J Immunother Cancer. 2025 Aug 14; 2025 Aug 14. PMID: 40813111.
• Humoral determinants of checkpoint immunotherapy.Dai Y, Aizenbud L, Qin K, Austin M, Jaycox JR, Cunningham J, Wang EY, Zhang L, Fischer S, Carroll SM, van Aggelen H, Kluger Y, Herold KC, Furchtgott L, Kluger HM, Ring AM. Nature. 2025 Aug; 2025 Jul 23. PMID: 40702172.
• Moving the Goalposts Closer: Using Intermediate End Points in Type 1 Diabetes Prevention Trials.Sydney GI, Wu SS, Herold KC. Diabetes Care. 2025 Aug 1. PMID: 40690655.
• Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding.Jacobsen LM, Felton JL, Nathan BM, Speake C, Krischer J, Herold KC. Diabetes Care. 2025 Jul 1. PMID: 40272284.
• Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes.Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long SA, McNamara J, Nguyen H, Serti E, Sumida TS, Herold KC. Nat Commun. 2025 May 30; 2025 May 30. PMID: 40447640.
• Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study.Quandt Z, Lucas A, Liang SI, Yang E, Stone S, Fadlullah MZH, Bayless NL, Marr SS, Thompson MA, Padron LJ, Bucktrout S, Butterfield LH, Tan AC, Herold KC, Bluestone JA, Anderson MS, Spencer CN, Young A, Connolly JE. J Immunother Cancer. 2025 May 12; 2025 May 12. PMID: 40355283.
• Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.Quandt Z, Perdigoto A, Anderson MS, Herold KC. Cold Spring Harb Perspect Med. 2025 Apr 1; 2025 Apr 1. PMID: 39038853.
• A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts.Sosenko JM, Cuthbertson D, Jacobsen LM, Redondo MJ, Sims EK, Ismail HM, Herold KC, Skyler JS, Nathan BM. Diabetes Technol Ther. 2025 Mar; 2025 Jan 6. PMID: 39757867.
• Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.Redondo MJ, Cuthbertson D, Steck AK, Herold KC, Oram R, Atkinson M, Brusko TM, Parikh HM, Krischer JP, Onengut-Gumuscu S, Rich SS, Sosenko JM. Diabetologia. 2025 Mar; 2024 Dec 13. PMID: 39670998.
• Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.Galderisi A, Sims EK, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan BM, Ismail HM, Herold KC, Moran A. Diabetologia. 2025 Mar; 2024 Nov 19. PMID: 39560746.
• Type 1 Diabetes: Advances in Understanding and Treatment 100 Years after the Discovery of Insulin.Bluestone JA, Herold KC, Sussel L. Cold Spring Harb Perspect Med. 2025 Feb 10; 2025 Feb 10. PMID: 39929731.
• Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop.Greenbaum CJ, Nepom GT, Wood-Heickman LK, Wherrett DK, DiMeglio LA, Herold KC, Krischer JP. Diabetes. 2024 Nov 1. PMID: 39167668.
• Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley PS, Long SA, Liu C, Koroleva G, Martins AJ, Tsang JS, Herold KC. J Clin Invest. 2024 Aug 13; 2024 Aug 13. PMID: 39137044.
• Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.Sims EK, Cuthbertson D, Jacobsen L, Ismail HM, Nathan BM, Herold KC, Redondo MJ, Sosenko J. J Clin Endocrinol Metab. 2024 Jul 12. PMID: 38267821.
• Prevention of Type 1 Diabetes.Jacobsen LM, Schatz DA, Herold KC, Skyler JS. 2023. PMID: 38843373.
• Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM. Diabetes Care. 2024 Jun 1. PMID: 38621411.
• Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes.Latres E, Greenbaum CJ, Oyaski ML, Dayan CM, Colhoun HM, Lachin JM, Skyler JS, Rickels MR, Ahmed ST, Dutta S, Herold KC, Marinac M. Diabetes. 2024 Jun 1. PMID: 38349844.
• The immunology of type 1 diabetes.Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK. Nat Rev Immunol. 2024 Jun; 2024 Feb 2. PMID: 38308004.
• A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes.Bender C, Wiedeman AE, Hu A, Ylescupidez A, Sietsema WK, Herold KC, Griffin KJ, Gitelman SE, Long SA. Sci Transl Med. 2024 May 8; 2024 May 8. PMID: 38718135.
• Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients.Abdel-Karim TR, Hodges JS, Herold KC, Pruett TL, Ramanathan KV, Hering BJ, Dunn TB, Kirchner VA, Beilman GJ, Bellin MD. Transpl Int. 2024; 2024 Jan 31. PMID: 38357216.
• A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.Mathieu C, Wiedeman A, Cerosaletti K, Long SA, Serti E, Cooney L, Vermeiren J, Caluwaerts S, Van Huynegem K, Steidler L, Blomme S, Rottiers P, Nepom GT, Herold KC. Diabetologia. 2024 Jan; 2023 Oct 2. PMID: 37782353.
• Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC. N Engl J Med. 2023 Dec 7; 2023 Oct 18. PMID: 37861217.
• High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.Sims EK, Geyer SM, Long SA, Herold KC. Diabetologia. 2023 Dec; 2023 Sep 4. PMID: 37667106.
• Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.Russell WE, Moore DJ, Herold KC. Diabetes Care. 2023 Nov 1. PMID: 37890101.
• Hydroxychloroquine in Stage 1 Type 1 Diabetes.Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC. Diabetes Care. 2023 Nov 1. PMID: 37708415.
• Immune responses to gut bacteria associated with time to diagnosis and clinical response to T cell-directed therapy for type 1 diabetes prevention.Xie QY, Oh S, Wong A, Yau C, Herold KC, Danska JS. Sci Transl Med. 2023 Oct 25; 2023 Oct 25. PMID: 37878676.
• Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Diabetes Care. 2023 Oct 1. PMID: 37607392.
• Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID-19 patients: Comparison with influenza and pre-pandemic data.Dell'Aquila K, Lee J, Wang SH, Alamuri TT, Jennings R, Tang H, Mahesh S, Leong TJ, Fleysher R, Henninger EM, Veeraraghavan S, Mirhaji P, Hou W, Herold KC, Duong TQ. Diabetes Obes Metab. 2023 Sep; 2023 May 30. PMID: 37254311.
• ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.Mann JE, Lucca L, Austin MR, Merkin RD, Robert ME, Al Bawardy B, Raddassi K, Aizenbud L, Joshi NS, Hafler DA, Abraham C, Herold KC, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586769.
• Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes.Delgado AL, Preston-Hurlburt P, Lim N, Sumida TS, Long SA, McNamara J, Serti E, Higdon L, Herold KC. medRxiv. 2023 Jul 13; 2023 Jul 13. PMID: 37502867.
• Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.Aizenbud L, Schoenfeld DA, Caulfield JI, Mann JE, Austin MR, Perdigoto AL, Herold KC, Kluger HM. J Immunother Cancer. 2023 Jun. PMID: 37349129.
• HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal.Pierce CA, Loh LN, Steach HR, Cheshenko N, Preston-Hurlburt P, Zhang F, Stransky S, Kravets L, Sidoli S, Philbrick W, Nassar M, Krishnaswamy S, Herold KC, Herold BC. J Clin Invest. 2023 Jun 1; 2023 Jun 1. PMID: 37079384.
• Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies.Sosenko JM, Cuthbertson D, Sims EK, Ismail HM, Nathan BM, Jacobsen LM, Atkinson MA, Evans-Molina C, Herold KC, Skyler JS, Redondo MJ. Diabetes Care. 2023 May 1. PMID: 37000695.
• Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC. Diabetes Care. 2023 May 1. PMID: 36920087.
• Incidence of new-onset in-hospital and persistent diabetes in COVID-19 patients: comparison with influenza.Lu JY, Wilson J, Hou W, Fleysher R, Herold BC, Herold KC, Duong TQ. EBioMedicine. 2023 Apr; 2023 Feb 28. PMID: 36857969.
• Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.Caulfield JI, Aizenbud L, Perdigoto AL, Meffre E, Jilaveanu L, Michalek DA, Rich SS, Aizenbud Y, Adeniran A, Herold KC, Austin MR, Kluger H. J Immunother Cancer. 2023 Mar. PMID: 36898736.
• CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.Wilson DM, Pietropaolo SL, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck AK, Vasudevan MM, McKay SV, Sherr JL, Herold KC, Dunne JL, Greenbaum CJ, Lord SM, Haller MJ, Schatz DA, Atkinson MA, Nelson PW, Pietropaolo M. Diabetes Care. 2023 Mar 1. PMID: 36730530.
• Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.Kinney M, You L, Sims EK, Wherrett D, Schatz D, Lord S, Krischer J, Russell WE, Gottlieb PA, Libman I, Buckner J, DiMeglio LA, Herold KC, Steck AK. J Endocr Soc. 2023 Jan 6; 2023 Jan 11. PMID: 36741943.
• Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening.Sims EK, Cuthbertson D, Felton JL, Ismail HM, Nathan BM, Jacobsen LM, Paprocki E, Pugliese A, Palmer J, Atkinson M, Evans-Molina C, Skyler JS, Redondo MJ, Herold KC, Sosenko JM. Diabetes Care. 2022 Dec 1. PMID: 36326757.
• RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.Joshi AA, Wu Y, Deng S, Preston-Hurlburt P, Forbes JM, Herold KC. Clin Immunol. 2022 Dec; 2022 Oct 17. PMID: 36257528.
• Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189-2201.Anderson RL, DiMeglio LA, Mander AP, Dayan CM, Linsley PS, Herold KC, Marinac M, Ahmed ST. Diabetes Care. 2022 Dec 1. PMID: 36219765.
• Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes.Anderson RL, DiMeglio LA, Mander AP, Dayan CM, Linsley PS, Herold KC, Marinac M, Ahmed ST. Diabetes Care. 2022 Oct 1. PMID: 36150059.
• The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J. Diabetes Care. 2022 Oct 1. PMID: 35998266.
• COVID-19 and children.Pierce CA, Herold KC, Herold BC, Chou J, Randolph A, Kane B, McFarland S, Gurdasani D, Pagel C, Hotez P, Cobey S, Hensley SE. Science. 2022 Sep 9; 2022 Sep 8. PMID: 36074833.
• Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC. JCI Insight. 2022 Sep 8; 2022 Sep 8. PMID: 35925682.
• Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity.Yang ML, Connolly SE, Gee RJ, Lam TT, Kanyo J, Peng J, Guyer P, Syed F, Tse HM, Clarke SG, Clarke CF, James EA, Speake C, Evans-Molina C, Arvan P, Herold KC, Wen L, Mamula MJ. Diabetes. 2022 Sep 1. PMID: 35730902.
• The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?Mallone R, Halliez C, Rui J, Herold KC. Diabetes. 2022 Aug 1. PMID: 35881836.
• Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets.Ben Nasr M, D'Addio F, Montefusco L, Usuelli V, Loretelli C, Rossi A, Pastore I, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Clark P, Nebuloni M, Baldi G, Finzi G, Folli F, Zuccotti GV, Galli M, Herold KC, Fiorina P. Diabetes. 2022 Jul 1. PMID: 35499468.
• Citrullination of glucokinase is linked to autoimmune diabetes.Yang ML, Horstman S, Gee R, Guyer P, Lam TT, Kanyo J, Perdigoto AL, Speake C, Greenbaum CJ, Callebaut A, Overbergh L, Kibbey RG, Herold KC, James EA, Mamula MJ. Nat Commun. 2022 Apr 6; 2022 Apr 6. PMID: 35388005.
• Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC. Diabetes. 2022 Apr 1. PMID: 35316839.
• Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.Jessel S, Weiss SA, Austin M, Mahajan A, Etts K, Zhang L, Aizenbud L, Perdigoto AL, Hurwitz M, Sznol M, Herold KC, Kluger HM. Front Oncol. 2022; 2022 Mar 8. PMID: 35350573.
• The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.Sims EK, Cuthbertson D, Herold KC, Sosenko JM. Diabetes. 2021 Dec; 2021 Sep 22. PMID: 34551936.
• IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S. JCI Insight. 2021 Nov 8; 2021 Nov 8. PMID: 34747368.
• Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count.So M, Speake C, Steck AK, Lundgren M, Colman PG, Palmer JP, Herold KC, Greenbaum CJ. Endocr Rev. 2021 Sep 28. PMID: 33881515.
• The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA. JCI Insight. 2021 Sep 22; 2021 Sep 22. PMID: 34324441.
• Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes.Rui J, Deng S, Perdigoto AL, Ponath G, Kursawe R, Lawlor N, Sumida T, Levine-Ritterman M, Stitzel ML, Pitt D, Lu J, Herold KC. Nat Commun. 2021 Aug 20; 2021 Aug 20. PMID: 34417463.
• Immunotherapy: Building a bridge to a cure for type 1 diabetes.Bluestone JA, Buckner JH, Herold KC. Science. 2021 Jul 30; 2021 Jul 29. PMID: 34326232.
• Natural mucosal barriers and COVID-19 in children.Pierce CA, Sy S, Galen B, Goldstein DY, Orner E, Keller MJ, Herold KC, Herold BC. JCI Insight. 2021 May 10; 2021 May 10. PMID: 33822777.
• Quantifying the effect of experimental perturbations at single-cell resolution.Burkhardt DB, Stanley JS 3rd, Tong A, Perdigoto AL, Gigante SA, Herold KC, Wolf G, Giraldez AJ, van Dijk D, Krishnaswamy S. Nat Biotechnol. 2021 May; 2021 Feb 8. PMID: 33558698.
• Adverse events induced by immune checkpoint inhibitors.Perdigoto AL, Kluger H, Herold KC. Curr Opin Immunol. 2021 Apr; 2021 Feb 25. PMID: 33640598.
• Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC. Sci Transl Med. 2021 Mar 3. PMID: 33658358.
• Natural Mucosal Barriers and COVID-19 in Children.Pierce CA, Sy S, Galen B, Goldstein DY, Orner E, Keller M, Herold KC, Herold B. medRxiv. 2021 Feb 13; 2021 Feb 13. PMID: 33594377.
• A little help from residual β cells has long-lasting clinical benefits.Lam A, Dayan C, Herold KC. J Clin Invest. 2021 Feb 1. PMID: 33529163.
• Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS. Annu Rev Med. 2021 Jan 27; 2020 Sep 4. PMID: 32886542.
• Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ. Diabetes Technol Ther. 2020 Dec; 2020 Oct 20. PMID: 32833543.
• Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Clin Oncol Case Rep. 2020 Nov; 2020 Sep 17. PMID: 33778814.
• Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS. Diabetes Obes Metab. 2020 Nov; 2020 Jul 29. PMID: 32573927.
• Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, Garforth SJ, Herrera NG, Jangra RK, Morano NC, Orner E, Sy S, Chandran K, Dziura J, Almo SC, Ring A, Keller MJ, Herold KC, Herold BC. Sci Transl Med. 2020 Oct 7; 2020 Sep 21. PMID: 32958614.
• The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling.Reed JC, Preston-Hurlburt P, Philbrick W, Betancur G, Korah M, Lucas C, Herold KC. PLoS One. 2020; 2020 Sep 28. PMID: 32986722.
• Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials.Sosenko JM, Skyler JS, Herold KC, Schatz DA, Haller MJ, Pugliese A, Cleves M, Geyer S, Rafkin LE, Matheson D, Palmer JP. Diabetes. 2020 Aug; 2020 May 21. PMID: 32439823.
• Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals.Ismail HM, Becker DJ, Libman I, Herold KC, Redondo MJ, Atkinson MA, Cleves MA, Palmer J, Sosenko J. Diabetes Obes Metab. 2020 Jun; 2020 Feb 27. PMID: 32003110.
• PET Imaging of Pancreatic Dopamine D(2) and D(3) Receptor Density with (11)C-(+)-PHNO in Type 1 Diabetes.Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold KC, Harris PE, Sherwin RS, Carson RE, Cline GW. J Nucl Med. 2020 Apr; 2019 Oct 10. PMID: 31601695.
• Circulating Unmethylated Insulin DNA As a Biomarker of Human Beta Cell Death: A Multi-laboratory Assay Comparison.Speake C, Ylescupidez A, Neiman D, Shemer R, Glaser B, Tersey SA, Usmani-Brown S, Clark P, Wilhelm JJ, Bellin MD, Herold KC, Mirmira RG, Dor Y, Evans-Molina C. J Clin Endocrinol Metab. 2020 Mar 1. PMID: 31913467.
• Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M. Diabetes Care. 2020 Jan; 2019 Nov 21. PMID: 31753960.
• Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes.Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD. JCI Insight. 2019 Dec 19; 2019 Dec 19. PMID: 31852846.
• Islet Harvest in Carbon Monoxide-Saturated Medium for Chronic Pancreatitis Patients Undergoing Islet Autotransplantation.Wang H, Gou W, Strange C, Wang J, Nietert PJ, Cloud C, Owzarski S, Shuford B, Duke T, Luttrell L, Lesher A, Papas KK, Herold KC, Clark P, Usmani-Brown S, Kitzmann J, Crosson C, Adams DB, Morgan KA. Cell Transplant. 2019 Dec; 2019 Dec 30. PMID: 31885286.
• Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply.Herold KC, Bundy BN, Krischer JP. N Engl J Med. 2019 Nov 7. PMID: 31693818.
• Changing the landscape for type 1 diabetes: the first step to prevention.Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Lancet. 2019 Oct 5; 2019 Sep 15. PMID: 31533907.
• β cell responses to inflammation.Usmani-Brown S, Perdigoto AL, Lavoie N, Clark P, Korah M, Rui J, Betancur G, Herold KC. Mol Metab. 2019 Sep. PMID: 31500821.
• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. N Engl J Med. 2019 Aug 15; 2019 Jun 9. PMID: 31180194.
• Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes.Simmons KM, Fouts A, Pyle L, Clark P, Dong F, Yu L, Usmani-Brown S, Gottlieb P, Herold KC, Steck AK. Int J Mol Sci. 2019 Aug 8; 2019 Aug 8. PMID: 31398795.
• Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.Ahmed S, Cerosaletti K, James E, Long SA, Mannering S, Speake C, Nakayama M, Tree T, Roep BO, Herold KC, Brusko TM. Diabetes. 2019 Jul. PMID: 31221801.
• Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ. Diabetes. 2019 Jun; 2019 Apr 9. PMID: 30967424.
• Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.Ismail HM, Evans-Molina C, DiMeglio LA, Becker DJ, Libman I, Sims EK, Boulware D, Herold KC, Rafkin L, Skyler J, Cleves MA, Palmer J, Sosenko JM. Pediatr Diabetes. 2019 Jun; 2019 Apr 15. PMID: 30891858.
• Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.Perdigoto AL, Quandt Z, Anderson M, Herold KC. Lancet Diabetes Endocrinol. 2019 Jun; 2019 Mar 15. PMID: 30885563.
• Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Diabetologia. 2019 Apr; 2018 Dec 19. PMID: 30569273.
• Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ. Genes Immun. 2019 Apr; 2018 Jun 21. PMID: 29925930.
• A Call for Improved Reporting of Human Islet Characteristics in Research Articles.Poitout V, Satin LS, Kahn SE, Stoffers DA, Marchetti P, Gannon M, Verchere CB, Herold KC, Myers MG Jr, Marshall SM. Diabetes. 2019 Feb; 2018 Dec 14. PMID: 30552106.
• A call for improved reporting of human islet characteristics in research articles.Poitout V, Satin LS, Kahn SE, Stoffers DA, Marchetti P, Gannon M, Verchere CB, Herold KC, Myers MG Jr, Marshall SM. Diabetologia. 2019 Feb; 2018 Dec 14. PMID: 30547229.